National Taiwan University

National Health Research Institutes

National Chung Hsing University

Taichung Veterans General Hospital

Gee-Chen Chang

Pan-Chyr Yang

Sung-Liang Yu

Hsuan-Yu Chen

Ko-Jiunn Liu

Neng-Yao Shih

Jian-Wei Chen

Bing-Ching Ho

Ker-Chau Li

Chih-Yi Chen

Disclosed herein is a method of determining whether a subject having or is at risk of developing lung cancer. The presence of the SNP locus of rs193100333, which corresponds to a mutation on YAP1 protein with a substitution of an arginine to a tryptophan at position 331, indicates the subject has or is at risk of developing lung cancer. Accordingly, also disclosed herein is a kit for facilitating the detection of the SNP locus of rs193100333.

Method or kit for determining lung cancer development

This invention provides a method for predicting the post-treatment survival prospect of a cancer patient based on the expression level(s) of microRNAs hsa-miR137, hsa-miR372, hsa-miR182*, hsa-miR221, and hsa-let-7a in that cancer patient.

Predicting post-treatment survival in cancer patients with microRNAs

This invention relates to a method of monitoring cancer development by determining the abundance of alpha-enolase protein wherein increased abundance is an indication of the severity of cancer. In another embodiment, the invention relates to a method of detecting cancer malignancy by determining the abundance of alpha-enolase antibodies in a sample wherein low levels of such antibodies indicates the malignancy of cancer. Also provided is a method of suppressing tumor growth by inducing the anti-ENO1 immune response.

Alpha-enolase specific antibody and method of use

Growing community of inventors

Taichung, Taiwan

Gee-Chen Chang